Filing Details

Accession Number:
0000886163-22-000125
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2022-09-22 20:32:50
Reporting Period:
2022-09-16
Accepted Time:
2022-09-22 20:32:50
Original Submission Date:
2022-09-16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1208906 L John Higgins 5980 Horton Street, Suite 405
Emeryville CA 94608
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-09-16 1,000 $88.06 366,180 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. On September 16, 2022, due to an issue with the equity administration system of the company, the reporting person filed a Form 4 which inadvertently reported the sale of a higher number of shares than were actually sold by the reporting person. The correct number of shares sold is listed above.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.05 to $88.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.